Top 10 / Long-term Top 10 — Health Care
Long-term Top 10 — Health Care
The 10 highest long-term scores among covered Health Care companies, rebalanced on the first trading day of each month.
Tracked against the market equal-weight, exits included
Top 10SPY (dashed)rebalance
+2.5% since 2026-08-18, against +0.2% for SPY — 2.3 points ahead of the benchmark. Tracked since 2026-08-18.
Get this list's changes by email
Who entered, who left, and the reason — with the score moves behind it.
Informational only — not financial advice. The daily email has not started yet — subscribing now puts you on the list for the first one. Unsubscribe in one click.
Where the cutoff sits
The cutoff today is 57.3 across 56 ranked Health Care companies. #11 (CHE) is 0.1 below it. A member leaves only if it falls past #15 — 55.7 today.
Changes at the 18 Aug 2026 rebalance
Entered
Amgen (AMGN) — Entered 18 Aug 2026: first selection for this list at rank 3, score 62.9.
Bristol Myers Squibb (BMY) — Entered 18 Aug 2026: first selection for this list at rank 6, score 59.1.
Quest Diagnostics (DGX) — Entered 18 Aug 2026: first selection for this list at rank 9, score 56.2.
Johnson & Johnson (JNJ) — Entered 18 Aug 2026: first selection for this list at rank 5, score 60.4.
LIGAND PHARMACEUTICALS INC (LGND) — Entered 18 Aug 2026: first selection for this list at rank 4, score 61.7.
Lilly (Eli) (LLY) — Entered 18 Aug 2026: first selection for this list at rank 1, score 66.0.
NATIONAL HEALTHCARE CORP (NHC) — Entered 18 Aug 2026: first selection for this list at rank 7, score 57.8.
ResMed (RMD) — Entered 18 Aug 2026: first selection for this list at rank 2, score 65.3.
Royalty Pharma (RPRX) — Entered 18 Aug 2026: first selection for this list at rank 8, score 57.2.
West Pharmaceutical Services (WST) — Entered 18 Aug 2026: first selection for this list at rank 10, score 56.2.
10 of 10 changed. This is the list’s first rebalance, so every member is new.
The 10 members
| # | Company · why it is here | Score | P | G | H | V | S | T | Sector rank | Price | Since entry | In the list since |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | Lilly (Eli) (LLY) Growth 97th (revenue growth year over year 49.6%, 3-year revenue CAGR 31.7%) and profitability 94th (return on equity 92.6%, operating margin 42.2%); weakest is valuation (10th, price to book 35.6, price to earnings 43). |
94 | 97 | 44 | 10 | 71 | 84 | 1 | 1280.34 19 Aug 2026 | +4.5% | 18 Aug 2026 | |
| 2 | Amgen (AMGN) Long-term trend 88th (it is at or near its highest point of the past year) and profitability 87th (return on equity 89.3%, operating margin 30.3%); weakest is valuation (26th, price to book 20.5, price to earnings 27.5). |
87 | 68 | 47 | 26 | 71 | 88 | 2 | 442.36 19 Aug 2026 | +4.0% | 18 Aug 2026 | |
| 3 | Johnson & Johnson (JNJ) Long-term trend 84th (it is 1.1% below its highest point of the past year) and profitability 75th (return on equity 25.7%, operating margin 25.7%); weakest is valuation (29th, price to book 7.8, price to earnings 31.7). |
75 | 54 | 69 | 29 | 71 | 84 | 3 | 273.41 19 Aug 2026 | +0.8% | 18 Aug 2026 | |
| 4 | ResMed (RMD) Financial health 88th (debt to equity 0.1, free cash flow margin 28.8%) and profitability 78th (operating margin 33.4%, return on equity 23.9%); weakest is long-term trend (26th, a "death cross" — its 50-day average is below its 200-day). |
78 | 71 | 88 | 53 | 71 | 26 | 4 | 230.65 19 Aug 2026 | +4.9% | 18 Aug 2026 | |
| 5 | Bristol Myers Squibb (BMY) Long-term trend 85th (a strong uptrend, with buyers in control) and profitability 81st (return on equity 46.8%, operating margin 25.5%); weakest is growth (29th, revenue growth year over year 3.1%, 3-year revenue CAGR 1.4%). |
81 | 29 | 55 | 57 | 71 | 85 | 5 | 67.61 19 Aug 2026 | +2.4% | 18 Aug 2026 | |
| 6 | NATIONAL HEALTHCARE CORP (NHC) Long-term trend 87th (over the past 12 months this stock beat the market by 93.9 percentage points) and shareholder return 71st (consecutive years of dividend increases 5 years); weakest is profitability (36th, operating margin 9.3%, return on equity 12.9%). |
36 | 63 | 68 | 50 | 71 | 87 | 6 | 234.04 19 Aug 2026 | −0.1% | 18 Aug 2026 | |
| 7 | Royalty Pharma (RPRX) Long-term trend 90th (it is at or near its highest point of the past year) and shareholder return 71st (consecutive years of dividend increases 5 years); weakest is valuation (31st, price to earnings 42.3, price to book 3.4). |
70 | 48 | 54 | 31 | 71 | 90 | 7 | 61.73 19 Aug 2026 | +3.4% | 18 Aug 2026 | |
| 8 | LIGAND PHARMACEUTICALS INC (LGND) Financial health 81st (free cash flow margin 44.9%, debt to equity 0.4) and growth 77th (3-year revenue CAGR 11%); weakest is shareholder return (11th, consecutive years of dividend increases 1 year). |
70 | 77 | 81 | 24 | 11 | 73 | 8 | 290.71 19 Aug 2026 | +1.1% | 18 Aug 2026 | |
| 9 | Quest Diagnostics (DGX) Long-term trend 90th (it is at or near its highest point of the past year) and shareholder return 71st (consecutive years of dividend increases 5 years); weakest is profitability (46th, operating margin 14.1%, return on equity 14.5%). |
46 | 52 | 47 | 49 | 71 | 90 | 9 | 241.76 19 Aug 2026 | +2.3% | 18 Aug 2026 | |
| 10 | West Pharmaceutical Services (WST) Financial health 73rd (debt to equity 0.1, free cash flow margin 13.1%) and shareholder return 71st (consecutive years of dividend increases 5 years); weakest is valuation (17th, price to earnings 45.1, price to book 8.3). |
63 | 52 | 73 | 17 | 71 | 69 | 10 | 352.79 19 Aug 2026 | +1.8% | 18 Aug 2026 |
Each bar is a percentile: how this company ranked against every company the score ranked, 0–100. The initials are the pillars of the Long-term score: P profitability, G growth, H financial health, V valuation, S shareholder return, T long-term trend.
Since entry is the price change from the day the member entered this list to its latest stored close.
How the score is built
The long-term score is a published weighted sum of percentile ranks, rebalanced on the first trading day of each month. A list is a published formula and its output, not a recommendation. Method version 2. Full method → What is the long-term score? →
Questions
How is the long-term score built?
The long-term score is a published weighted sum of percentile ranks, rebalanced on the first trading day of each month. A list is a published formula and its output, not a recommendation. Method version 2. Each bar is a percentile: how this company ranked against every company the score ranked, 0–100.
How often does this list change?
Members are rebalanced on the first trading day of each month. Scores are recomputed nightly, but membership only changes at a scheduled rebalance, or immediately if a company stops being eligible. A member is held while it stays inside the top 15, so a small move in rank does not force a change.
What score does a company need to be in this list?
The cutoff today is 57.3 across 56 ranked Health Care companies. #11 (CHE) is 0.1 below it. A member leaves only if it falls past #15 — 55.7 today.
Informational only — NOT financial advice.